Vagus Nerve Stimulator for Autism and Other Developmental Disorders — VNS  

Autism Spectrum Disorder Clinical Trial

Official title: Vagus Nerve Stimulation for Autonomic Dysregulation in Individuals With Developmental Disorders

Status Recruiting

Clinical Trial Summary

The goal of this flexible single-subject design vagus nerve stimulation (VNS) study is to examine the behavioral, cognitive, and biorhythmic effects of VNS in children and adults with autism and developmental disabilities. The main aims are:

• Pilot the creation of a profile for those who will respond to VNS with the long-term goal of designing clinical trials.

• Examine the effects of VNS on a broad range of symptoms.

Participants will select between 1, 2, or 3 months of daily VNS treatment and complete study visits each month.

Clinical Trial Description

Intellectual and developmental disabilities (IDD) cover a wide variety of disorders. Although we know the causes of some of the disorders and some of them could even be prevented (e.g., lead exposure), most causes remain unknown. Without having a clear understanding of the causes, prevention is very difficult to achieve. Previous studies have shown abnormal autonomic nervous system (ANS) regulations in young children with autism spectrum disorder (ASD) and these abnormalities are also observed during sleep. ANS is the part of the nervous system that controls the unconscious bodily functions, such as breathing, heart beating, and digestion.

The vagus nerve strongly influences these autonomic functions including digestion, breathing, heart rate variability, and metabolic function and central nervous system (CNS) activity that affect mood, pain, stress management, sleep, and even memory and cognitive functions. The vagal influence over neurotransmitter release has been implicated in the regulation of inflammation and immune cell activity.

Here, we are using a non-invasive vagus nerve stimulator to monitor changes in cognitive function and other symptoms in people with IDD, both with and without ASD. The device is FDA-approved for migraine and cluster headaches in people 12 years and older. VNS activates the vagus nerve with mild electrical stimulation through the skin.

Rather than embarking on a rigorously designed study, we will conduct a series of single-subject studies that reflects each participant's symptoms. We will select the most appropriate dependent variables based on each person's symptom presentation. ;

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autonomic Nervous System
• Developmental Disabilities
• Developmental Disability
• Intellectual Disability

• NCT number: NCT06259201
• Study type: Interventional
• Source: New York State Institute for Basic Research
• Contact: Helen Yoo, Ph.D.
• Phone: 718-494-5295
• Email: jhelen.yoo@opwdd.ny.gov
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2024
• Completion date: December 2026